Tidepath

Peptide library

The GLP-1 family

One receptor, then two, then three.

This family is named after "GLP-1". The name fits semaglutide exactly and is incomplete for tirzepatide and retatrutide.

GLP-1 is a hormone your gut releases after you eat. It belongs to a small group of gut hormones called incretins, which tell the pancreas to release insulin. GLP-1 also slows how fast the stomach empties and tells the brain you're full. Your own incretins break down within minutes. These drugs are made to act on the same receptors for much longer. That long action is what allows a weekly dose: semaglutide and tirzepatide are labelled for a once-weekly injection, and retatrutide was given once a week in the phase 2 and phase 3 trials in our sources. Semaglutide also comes as a daily pill.

Each one goes a step further than the last. Semaglutide acts on one incretin receptor. Tirzepatide acts on two. Retatrutide adds a third receptor, for glucagon, a hormone that raises blood sugar. That receptor works in a different way. Each step is a real difference in how the drug acts, not just a new brand.

In this group

Why the injections are weekly

All three stay in the body for days, not hours. Each has a half-life, the time it takes for half a dose to clear, of several days. That's what makes once-a-week dosing possible, and it means levels rise and fall gradually instead of wearing off between doses. After a dose change, it takes several weeks of weekly doses for levels to get close to the same weekly pattern at the new dose (called steady state).

What we don't cover

These pages say where each drug's doses come from and how long each drug lasts. They don't cover side effects, who shouldn't take these drugs (contraindications), or drug interactions yet, with one exception: semaglutide's and tirzepatide's pages say what animal studies found about thyroid tumors, the finding behind the warning boxed on their labels. For the rest, read the label where there is one, and ask a doctor.

Related: Amylin drugs, More GLP-1 drugs, GLP-1 and glucagon drugs

Get an early invite to Tidepath

The app isn't in the App Store yet. Leave your email for an early invite, and tips for your first month.

Get an early invite, tips and occasional news from Tidepath. Unsubscribe anytime. Privacy · Health data privacy · Sender and contact details